Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3978692 | Bulletin du Cancer | 2012 | 7 Pages |
Abstract
Abiraterone acetate and cabazitaxel have shown an overall survival benefit in patients with metastatic castration-resistant prostate cancer following docetaxel failure. Both have been approved in this indication. The search, follow-up and characterisation of circulating tumor cells should help for the response evaluation and the choice between the two treatments. Recently, alpharadin (radium-223 chloride) has demonstrated also an overall survival advantage in a large phase III trial. Other hormone therapies as MDV3100 or TAK700 are very promising. In undifferentiated cancers with neuroendocrine features, etoposide and platinum salts combinations have shown low efficiency
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Philippe Beuzeboc, Stanislas Ropert, FranÃois Goldwasser, Marc Zerbib,